Blood Cancer United has awarded a $2.5 million grant to a research team led by Melissa Beauchemin to improve clinical trial participation among adolescents, young adults, and older adults with blood cancer. The study aims to address barriers to access and participation, including delayed identification and fragmented referral pathways.
The collaboration aims to improve outcomes for patients with myelodysplastic syndromes (MDS) through a five-year multidisciplinary research program. MDS affects approximately 10,000 to 15,000 people in the US each year, and research is needed to address the urgent need for more effective treatment options.
A $7 million funding boost will help researchers better understand hairy cell leukemia and develop more effective treatments, particularly for patients with variant disease and those who relapse. The grants will focus on improving patient outcomes and closing the gap in treatment options.